MedTrace Logo

CAE for Poorly Adherent Individuals With Schizophrenia

NCT06061952 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-11-18

Study results available
· View outcomes & findings →

Summary

This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).

Conditions

Interventions

BEHAVIORAL

Customized Adherence Enhancement for Schizophrenia (CAE-S)

6-session series spaced out over approximately 6-10 weeks

OTHER

Enhanced Treatment as Usual (eTAU)

eTAU participants will view a pre-taped series of 6 videos

Sponsors & Collaborators

Principal Investigators

  • Martha Sajatovic, MD · University Hospitals Cleveland Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-16
Primary Completion
2025-08-09
Completion
2025-08-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06061952 on ClinicalTrials.gov